MedTrace Logo

Study of Whether 15 mg Dose of Ketorolac IV is as Effective as a 30 mg Dose.

NCT01230463 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2010-10-29

No results posted yet for this study

Summary

The primary aim of this study is to show the non-inferiority of 15 mg intraoperative dose of ketorolac as compared to the standard 30 mg ketorolac by looking at the VAS scores 4 hours after an adult spine surgery.

Conditions

  • Pain
  • Pain, Postoperative

Interventions

DRUG

Ketorolac Tromethamine

15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.

DRUG

Ketorolac Tromethamine

30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Principal Investigators

  • Kaylene Duttchen, MD · University of Calgary - Department of Anesthesia

  • Melinda Davis, MD · University of Calgary - Department of Anesthesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01230463 on ClinicalTrials.gov